Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Despite high enthusiasm, early attempts to develop clinical treatments based on animal research with neurotrophins were not successful. Here we survey clinical trials with neurotrophins, compared with neurotrophic factors of other gene families, and delineate the most likely reasons for their failure. We then suggest improved methods for regulated local supply of NTs to specific populations of neurons and discuss future therapeutic procedures evolving from the more detailed knowledge of the signal transduction pathways activated by neurotrophins via their receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since the discovery of BDNF and its receptor TrkB, efforts have been made to use BDNF as a therapeutic agent for neuropsychiatric disorders or to develop small-molecule pharmaceuticals that could increase the production of BDNF or activate TrkB in brain (for review, see99,100), and these efforts are still ongoing101.”
From Neuronal plasticity and neurotrophic factors in drug responses (2017) · cites this paper as [99]
In the citing paper
“A lack of methods for effectively and safely delivering growth factors to the nervous system over sustained time periods has been a major factor limiting their translational testing32.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [32]
Citations
Cites
Exercise: a behavioral intervention to enhance brain health and plasticity
Cotman, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02143-4 · Cited by 2,739 · cited 1×
“New, therapeutically interesting perspectives evolved from the observation that physical exercise evokes a marked increase in BDNF levels in the rat brain, in particular in the hippocampus and cerebral corte”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundNEUROTROPHINS AND SYNAPTIC PLASTICITY
McAllister, A. K., Katz, L. C., & Lo, D. C. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.295 · Cited by 1,337 · cited 1×
“This decisive statement can be made because NTs, besides regulating survival, differentiation and maintenance of neuron-specific characteristics (for example, neurotransmitters and neuropeptides), also are important in modulating activity-dependent neuronal plasticity, essential for the functional and structural refin…”
BackgroundNerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“Although (unregulated) overexpression of neurotrophic molecules by viral vectors has already provided encouraging result”
BackgroundHuang, Z. J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., & Tonegawa, S. (1999) · Cell · doi:10.1016/s0092-8674(00)81509-3 · Cited by 1,198 · cited 1×
“For the treatment of neurons that are themselves directly involved in the formation of neuronal circuits, modified in a refined manner by neuronal activity, the local overexpression of NTs could result in functional disturbances, as for example demonstrated in the visual cortex by the local transgenic overexpression o…”
BackgroundHANDBOOK OF EXPERIMENTAL PHARMACOLOGY
Reichlin, S. (1969) · The American Journal of The Medical Sciences · doi:10.1097/00000441-196911000-00008 · Cited by 1,134
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system
Bibel, M., & Barde, Y.-A. (2000) · Genes & Development · doi:10.1101/gad.841400 · Cited by 1,065
Fischer, W., Wictorin, K., Björklund, A., Williams, L. R., Varon, S., & Gage, F. H. (1987) · Nature · doi:10.1038/329065a0 · Cited by 1,024
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Anthony Altar, C., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 788 · cited 1×
“Other members of the NT family were linked to a much broader spectrum of biological action”
BackgroundCirculating Insulin-Like Growth Factor I Mediates Effects of Exercise on the Brain
Carro, E., Nuñez, A., Busiguina, S., & Torres-Aleman, I. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02926.2000 · Cited by 762 · cited 1×
“These initial observations took an interesting turn when it was detected that the increased levels of BDNF are mediated by the enhanced production of growth hormone in the periphery, followed by increased synthesis of IGF-1 (ref”
BackgroundThe nerve growth factor: thirty-five years later.
Levi-Montalcini, R. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02347.x · Cited by 718
Carro, E., Trejo, J. L., Busiguina, S., & Torres-Aleman, I. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05678.2001 · Cited by 601
Sendtner, M., Schmalbruch, H., Stöckli, K. A., Carroll, P., Kreutzberg, G. W., & Thoenen, H. (1992) · Nature · doi:10.1038/358502a0 · Cited by 552
Self-citationElectrical activity and development of neural circuits
Zhang, L. I., & Poo, M.-M. (2001) · Nature Neuroscience · doi:10.1038/nn753 · Cited by 531 · cited 1×
“This decisive statement can be made because NTs, besides regulating survival, differentiation and maintenance of neuron-specific characteristics (for example, neurotransmitters and neuropeptides), also are important in modulating activity-dependent neuronal plasticity, essential for the functional and structural refin…”
BackgroundCritical periods during sensory development
Berardi, N., Pizzorusso, T., & Maffei, L. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(99)00047-1 · Cited by 489 · cited 1×
“This decisive statement can be made because NTs, besides regulating survival, differentiation and maintenance of neuron-specific characteristics (for example, neurotransmitters and neuropeptides), also are important in modulating activity-dependent neuronal plasticity, essential for the functional and structural refin…”
BackgroundIntracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
Eriksdotter Jönhagen, M., Nordberg, A., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472
BDNF and epilepsy: too much of a good thing?
Binder, D. K., Croll, S. D., Gall, C. M., & Scharfman, H. E. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01682-9 · Cited by 454 · cited 1×
“Accordingly, the indiscriminate administration of NTs interferes with such mechanisms and may even initiate immediate serious side effects, such as epileptic activit”
A controlled trial of recombinant methionyl human BDNF in ALS
The BDNF Study Group (Phase III) (1999) · Neurology · doi:10.1212/wnl.52.7.1427 · Cited by 451
Aebischer, P., Schluep, M., Déglon, N., Joseph, J.-M., Hirt, L., Heyd, B., Goddard, M., Hammang, J. P., Zurn, A. D., Kato, A. C., et al. (1996) · Nature Medicine · doi:10.1038/nm0696-696 · Cited by 446
Donovan, M. J., Lin, M. I., Wiegn, P., Ringstedt, T., Kraemer, R., Hahn, R., Wang, S., Ibañez, C. F., Rafii, S., & Hempstead, B. L. (2000) · Development · doi:10.1242/dev.127.21.4531 · Cited by 435
ALS CNTF Treatment Study Group (1996) · Neurology · doi:10.1212/wnl.46.5.1244 · Cited by 405
Arrest of Motor Neuron Disease in wobbler Mice Cotreated with CNTF and BDNF
Mitsumoto, H., Ikeda, K., Klinkosz, B., Cedarbaum, J. M., Wong, V., & Lindsay, R. M. (1994) · Science · doi:10.1126/science.8066451 · Cited by 386
Nerve growth factor and Alzheimer's disease
Hefti, F., & Weiner, W. J. (1986) · Annals of Neurology · doi:10.1002/ana.410200302 · Cited by 382 · cited 1×
“This proposal was based on the observation that the basal forebrain cholinergic neurons are consistently affected at an early stage of Alzheimer's diseas”
BackgroundApfel, S. C., Schwartz, S., Adornato, B. T., Freeman, R., Biton, V., Rendell, M., Vinik, A., Giuliani, M., Stevens, J. C., Barbano, R., et al. (2000) · JAMA · doi:10.1001/jama.284.17.2215 · Cited by 368
Lai, E. C., Felice, K. J., Festoff, B. W., Gawel, M. J., Gelinas, D. F., Kratz, R., Murphy, M. F., Natter, H. M., Norris, F. H., Rudnicki, S. A., et al. (1997) · Neurology · doi:10.1212/wnl.49.6.1621 · Cited by 361
Miller, R. G., Petajan, J. H., Bryan, W. W., Armon, C., Barohn, R. J., Goodpasture, J. C., Hoagland, R. J., Parry, G. J., Ross, M. A., Stromatt, S. C., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390215 · Cited by 345
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
Borasio, G. D., Robberecht, W., Leigh, P. N., Emile, J., Guiloff, R. J., Jerusalem, F., Silani, V., Vos, P. E., Wokke, J. H. J., Dobbins, T., et al. (1998) · Neurology · doi:10.1212/wnl.51.2.583 · Cited by 340
The nerve growth factor family
Barde, Y.-A. (1990) · Progress in Growth Factor Research · doi:10.1016/0955-2235(90)90021-b · Cited by 328 · cited 1×
“The cloning of brain-derived neurotrophic factor (BDNF) demonstrated that NGF is a member of a gene family dubbed neurotrophins (NTs”
BackgroundHempstead, B. (2002) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(02)00321-5 · Cited by 321
Ochs, G., Penn, R. D., York, M., Giess, R., Beck, M., Tonn, J., Haigh, J., Malta, E., Traub, M., Sendtner, M., et al. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820050515197 · Cited by 302
Self-citationRecombinant human nerve growth factor in the treatment of diabetic polyneuropathy
Apfel, S. C., Kessler, J. A., Adornato, B. T., Litchy, W. J., Sanders, C., Rask, C. A., & The NGF Study Group* (1998) · Neurology · doi:10.1212/wnl.51.3.695 · Cited by 289
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
McArthur, J. C., Yiannoutsos, C., Simpson, D. M., Adornato, B. T., Singer, E. J., Hollander, H., Marra, C., Rubin, M., Cohen, B. A., Tucker, T., et al. (2000) · Neurology · doi:10.1212/wnl.54.5.1080 · Cited by 286
Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H., & Hohlfeld, R. (2003) · Annals of Neurology · doi:10.1002/ana.10446 · Cited by 273
TrkB Gene Transfer Protects Retinal Ganglion Cells from Axotomy-Induced Death In Vivo
Cheng, L., Sapieha, P., Kittlerová, P., Hauswirth, W. W., & Di Polo, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-10-03977.2002 · Cited by 254
McKay, R. (2000) · Nature · doi:10.1038/35019186 · Cited by 249
A new concept in neurodegeneration: TNFα is a silencer of survival signals
Venters, H. D., Dantzer, R., & Kelley, K. W. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01533-7 · Cited by 194
PHARMACOLOGY OF NEUROTROPHIC FACTORS
Hefti, F. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.239 · Cited by 186 · cited 1×
“A fair number of identified compounds show at least partially the desired therapeutic effects, mainly survival activity or augmented synthesis of NT”
BackgroundRecombinant human nerve growth factor in the treatment of diabetic polyneuropathy
Riggs, J. E., Apfel, S. C., Litchy, W. J., Kessler, J. A., Sanders, C., Adornato, B. T., & Rask, C. A. (1999) · Neurology · doi:10.1212/wnl.52.7.1517-a · Cited by 182
Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors
Lee, F. S., Rajagopal, R., & Chao, M. V. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00024-7 · Cited by 177
Bachoud-Lévi, A.-C., Déglon, N., Nguyen, J.-P., Bloch, J., Bourdet, C., Winkel, L., Rémy, P., Goddard, M., Lefaucheur, J.-P., Brugières, P., et al. (2000) · Human Gene Therapy · doi:10.1089/10430340050111377 · Cited by 171
Gravel, C., Götz, R., Lorrain, A., & Sendtner, M. (1997) · Nature Medicine · doi:10.1038/nm0797-765 · Cited by 170 · cited 1×
“Although (unregulated) overexpression of neurotrophic molecules by viral vectors has already provided encouraging result”
BackgroundSelf-citationVigna, E., Cavalieri, S., Ailles, L., Geuna, M., Loew, R., Bujard, H., & Naldini, L. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0542 · Cited by 150
Knüsel, B., Gao, H., Okazaki, T., Yoshida, T., Mori, N., Hefti, F. F., & Kaplan, D. R. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00616-1 · Cited by 136 · cited 1×
“It is possible that the relatively high concentrations of BDNF supplied to the motoneurons caused downregulation of Trk receptors, as demonstrated in rodents in different populations of neurons in vitro and in vivo”
BackgroundTetracycline-regulated gene expression in the brain
Mansuy, I. M., & Bujard, H. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00127-6 · Cited by 125 · cited 1×
“Indeed, suitable expression systems have been developed, which take advantage of heterologous transcription factors that can be regulated by low molecular weight ligands such as derivatives of tetracycline or steroid”
BackgroundRecent advances in inducible gene expression systems
Rossi, F. M., & Blau, H. M. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80028-1 · Cited by 115 · cited 1×
“Indeed, suitable expression systems have been developed, which take advantage of heterologous transcription factors that can be regulated by low molecular weight ligands such as derivatives of tetracycline or steroid”
BackgroundWellmer, A., Misra, V. P., Sharief, M. K., Kopelman, P. G., & Anand, P. (2001) · Journal of the Peripheral Nervous System · doi:10.1046/j.1529-8027.2001.01019.x · Cited by 111
Penn, R. D., Kroin, J. S., York, M. M., & Cedarbaum, J. M. (1997) · Neurosurgery · doi:10.1097/00006123-199701000-00021 · Cited by 108
Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy
Schifitto, G., Yiannoutsos, C. T., Simpson, D. M., Adornato, B. T., Singer, E. J., Hollander, H., Marra, C. M., Rubin, M., Cohen, B. A., Tucker, T., et al. (2001) · Neurology · doi:10.1212/wnl.57.7.1313 · Cited by 106
The response of motoneurons to neurotrophins
Sendtner, M., Holtmann, B., & Hughes, R. A. (1996) · Neurochemical Research · doi:10.1007/bf02532307 · Cited by 88
Self-citationPharmacokinetics of Intrathecally Applied BDNF and Effects on Spinal Motoneurons
Dittrich, F., Ochs, G., Große-Wilde, A., Berweiler, U., Yan, Q., Miller, J. A., Toyka, K. V., & Sendtner, M. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0157 · Cited by 83
Self-citationAxonal Regeneration in the Central Nervous System
Jeffery, N. D. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2001.00350-2.x · Cited by 73
&NA; (1995) · Clinical Neuropharmacology · doi:10.1097/00002826-199512000-00004 · Cited by 70
Axonal Regeneration in the Central Nervous System
Murray, M., & Ingoglia, N. A. (2000) · Medical Entomology and Zoology · Cited by 61
Gene therapeutic strategies for neurodegenerative diseases.
Baekelandt, V., Strooper, B. D., Nuttin, B., & Debyser, Z. (2000) · PubMed · Cited by 40
Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects
Chaudhry, V., Giuliani, M., Petty, B. G., Lee, D., Seyedsadr, M., Hilt, D. C., & Cornblath, D. R. (2000) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(200002)23:2<189::aid-mus7>3.0.co;2-8 · Cited by 33
Muscle fiber conduction velocity in arg1239his mutation in hypokalemic periodic paralysis
Links, T. P., & van der Hoeven, J. H. (2000) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(200002)23:2<164::aid-mus4>3.0.co;2-y · Cited by 14
Research works printed but not linked: 1
- Lowenstein, P.R. & Enquist, L.W. Protocols for Gene Transfer in Neuroscience (Wiley, Chichester, UK, 1996).
Cited by
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Miranda, M., Morici, J. F., Zanoni, M. B., & Bekinschtein, P. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00363 · Cited by 1,416
“Moreover, gene therapy and BDNF mimetic strategies came across many negative side effects that led to their abandonment (Thoenen and Sendtner, 2002).”
BackgroundNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Metadata
- Authors
- Thoenen, H., & Sendtner, M.
- Affiliations
- Max Planck Society (DE)
- University of Würzburg (DE)
- ORCID
- Sendtner, Michael
- Venue
- Nature Neuroscience
- Published
- 2002-10-28
- Volume
- 5
- Issue
- S11
- Pages
- 1046-1050
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2058026578
- Cited by
- 336
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 19 · 2018: 9 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 10 · 2013: 17 · 2012: 17
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Eli Lilly and Company
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- neurotrophins, neurotrophic factors, clinical trials, treatment failure, neurotrophin receptors, signal transduction, gene therapy
- MeSH terms
- Animals, Central Nervous System Diseases, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Humans, Nerve Growth Factors, Peripheral Nervous System Diseases, Drug Design, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.